Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the current treatment landscape in Tardive Dyskinesia post Ingrezza and Austedo approval

Ticker(s): NBIX, TEVA

Who's the expert?

Name: Dr Joseph Jankovic - MD

Institution: Baylor College of Medicine 

  • Professor of Neurology, Distinguished Chair in Movement Disorders, Founder & Director of the Parkinson’s Disease Center and Movement Disorders Clinic at Baylor.
  • Currently has 5 of 250 patients with Tardive Dyskinesia on Ingrezza.
  • Participated in the pivotal Huntington's Disease trial for Austedo.

Interview Questions
Q1.

Please tell us about your clinical practice, background in treating Tardive Dyskinesia and research in the space. How many patients do you treat, and what is the first line of choice?

Added By: slingshot_insights
Q2.

How much of a need for new treatments is still there? Which drug is becoming the golden standard?

Added By: slingshot_insights
Q3.

What % of patients with tardive dyskinesia don’t have as good a response under Austedo or Ingrezza as you would expect?

Added By: slingshot_insights
Q4.

What is the clinical significance of inhibiting vesicular monoamine transporter 2/VMAT2 with a drug like Ingrezza or Austedo?

Added By: slingshot_insights
Q5.

Have there been any serious cases of Drug-induced QT prolongation in patients using Ingrezza or Austedo post approval?

Added By: slingshot_insights
Q6.

How does Ingrezza’s ~30% Reduction in TD Severity at 6 Weeks compare to other drugs on the market, and to Austedo more specifically?

Added By: slingshot_insights
Q7.

What percent of the patient population has both Huntington’s disease chorea and TD, and is Austedo always the treatment of choice in those cases, as its label would imply?

Added By: slingshot_insights
Q8.

Do they view their patients as mild, moderate, severe, or “just TD” – does it matter severity for who starts and when? NBIX says it does not.

Added By: joe_mccann
Q9.

 Is VMAT2 an important mechanism for other neuro conditions, if so, which ones?

Added By: joe_mccann
Q10.

How is access? Payors now aware that this is becoming a big drug and may restrict access going forward…

Added By: joe_mccann
Q11.

What is your current share of Ingrezza vs. Austedo? How has it changed overtime and how do you expect it to change in the future?

Added By: joe_mccann
Q12.

What is compliance? Duration on therapy?

Added By: joe_mccann
Q13.

Does it help that NBIX has a specialty distribution network that calls you 10 days before Rx runs out? Does Teva do this?

Added By: joe_mccann
Q14.

What are the differences in marketing for the Neurocrine team vs Teva’s team?

Added By: joe_mccann
Q15.

Why use Ingrezza vs. Austedo and why?

Added By: joe_mccann
Q16.

 Is Ingrezza’s dosing advantage (no titration schedule) meaningful when deciding between the two therapies?

Added By: joe_mccann
Q17.

Neurocrine cited an issue at the beginning of this year with insurance reauthorizations – that cause a good portion of patients to not receive their first Rx of 2019 until February, did you have any similar issues with your patients this year? If so, can you talk through that dynamic?

Added By: joe_mccann
Q18.

How large is the addressable TD market? The companies estimate the prevalence may be at least 500,000 in the US but realistically what % of these patients will ultimately be diagnosed and treated?

Added By: joe_mccann
Q19.

What are the off label indications you have treated with Ingrezza or Austedo and did you see a response?

Added By: user8c9e0ac1

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.